Literature DB >> 23673438

Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors.

Theodoros Dimitroulas1, Karen M J Douglas, Vasileios F Panoulas, Tracey Toms, Jacqueline P Smith, Gareth J Treharne, Peter Nightingale, James Hodson, George D Kitas.   

Abstract

Disturbance of fibrinolysis is common in rheumatoid arthritis (RA), and it may be associated with the increased cardiovascular risk observed in this population. We aimed to assess coagulation derangement and investigate whether abnormalities are influenced by demographic, inflammatory or metabolic factors in patients with RA. Levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1), fibrinogen, prothrombin fragment 1 + 2 (PF1 + 2), thrombomodulin (TM), protein C and Von Willebrand factor (vWF) were compared between 141 RA patients and 50 healthy hospital controls. Within RA, coagulation factors were assessed alongside several demographic, inflammation and metabolic indicators. RA patients had higher levels of coagulation factors than controls. After correction for age and sex, having RA predicted increased tPA (B = 0.15, P < 0.001), PAI-1 (B = 0.21, P < 0.001), fibrinogen (B = 0.86, P < 0.001), PF1 + 2 (B = 0.20, P < 0.001), and TM (B = 0.01, P = 0.03) levels. CRP correlated positively with tPA (P < 0.05), fibrinogen (P < 0.001), TM (P < 0.05), PF1 + 2 (P < 0.001) and vWF (P < 0.001). Metabolic factors linked with coagulation factors were hypertriglyceridaemia (tPA, P < 0.05; PAI-1, P < 0.05; protein C, P < 0.05) and insulin resistance (tPA, P < 0.01; PAI-1, P < 0.01; vWF, P < 0.05). Imbalance of coagulation and fibrinolytic mechanisms is common in RA and associates with age, inflammation, and metabolic factors. Further studies may determine whether these abnormalities are the consequence of acute inflammation or markers of vascular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23673438     DOI: 10.1007/s10067-013-2283-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  53 in total

Review 1.  Regulation of plasminogen activators and their inhibitors in rheumatic diseases: new understanding and the potential for new directions.

Authors:  D A Hart; M J Fritzler
Journal:  J Rheumatol       Date:  1989-09       Impact factor: 4.666

2.  Insulin resistance and impaired beta cell function in rheumatoid arthritis.

Authors:  Patrick H Dessein; Barry I Joffe
Journal:  Arthritis Rheum       Date:  2006-09

3.  Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity.

Authors:  L T Kopeikina; E F Kamper; V Koutsoukos; Y Bassiakos; I Stavridis
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

4.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

5.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.

Authors:  I D del Rincón; K Williams; M P Stern; G L Freeman; A Escalante
Journal:  Arthritis Rheum       Date:  2001-12

6.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction.

Authors:  P M Ridker; D E Vaughan; M J Stampfer; J E Manson; C H Hennekens
Journal:  Lancet       Date:  1993-05-08       Impact factor: 79.321

Review 7.  Hypertension in rheumatoid arthritis.

Authors:  V F Panoulas; G S Metsios; A V Pace; H John; G J Treharne; M J Banks; G D Kitas
Journal:  Rheumatology (Oxford)       Date:  2008-05-08       Impact factor: 7.580

8.  Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis.

Authors:  Frederick Wolfe; Bruce Freundlich; Walter L Straus
Journal:  J Rheumatol       Date:  2003-01       Impact factor: 4.666

9.  Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population.

Authors:  Alicja R Rudnicka; Ann Rumley; Gordon D O Lowe; David P Strachan
Journal:  Circulation       Date:  2007-02-12       Impact factor: 29.690

10.  Association between venous thromboembolism and plasma levels of both soluble fibrin and plasminogen-activator inhibitor 1 in 170 patients undergoing total hip arthroplasty.

Authors:  Yohei Yukizawa; Yutaka Inaba; Shin-ichiro Watanabe; Satoshi Yajima; Naomi Kobayashi; Takashi Ishida; Naoyuki Iwamoto; Hyonmin Choe; Tomoyuki Saito
Journal:  Acta Orthop       Date:  2012-01-17       Impact factor: 3.717

View more
  4 in total

1.  Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade.

Authors:  Konstantinos Makrilakis; Kalliopi Fragiadaki; Jacqueline Smith; Petros P Sfikakis; George D Kitas
Journal:  Clin Rheumatol       Date:  2014-06-10       Impact factor: 2.980

Review 2.  The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets.

Authors:  Benjamin J Buckley; Umar Ali; Michael J Kelso; Marie Ranson
Journal:  Curr Drug Targets       Date:  2019       Impact factor: 3.465

3.  Acquired coagulation dysfunction resulting from vitamin K-dependent coagulation factor deficiency associated with rheumatoid arthritis: A case report.

Authors:  Yan-Jing Huang; Liang Han; Jing Li; Chao Chen
Journal:  World J Clin Cases       Date:  2022-01-07       Impact factor: 1.337

4.  Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation.

Authors:  Theodoros Dimitroulas; James Hodson; Aamer Sandoo; Jacqueline Smith; George D Kitas
Journal:  Arthritis Res Ther       Date:  2017-02-10       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.